All Videos

A systemic-naive roofer with extensive plaque psoriasis and cardiometabolic risk illustrates why compliance history, not just disease severity, should shape the first conversation about moving beyond topical therapy.

As biologics multiply, the boundary between topical failure and systemic eligibility remains contested. Dr. Armstrong outlines the severity thresholds, comorbidities, and quality-of-life factors that most reliably justify escalating plaque psoriasis therapy.

Dermatology Times and NPPA Connect celebrate National APP Week 2026 by highlighting the voices, experiences, and impact of advanced practice providers in dermatology.

Explore what drives male pattern hair loss, its emotional toll, and why new topical antiandrogen clascoterone may boost density while limiting systemic effects.

Lauren Miller, PA-C, reflects on nearly 20 years in dermatology and how the PA profession has allowed her to grow as a clinician, educator, author, and mentor.

On this episode of Don't Be Rash, Lisa Swanson, MD, joined host Andrew C. Krakowski, MD, to walk through the pediatric psoriasis treatment ladder, from first-line topicals to biologics and a new oral IL-23 blocker.

For Alopecia Awareness Month, Deann of Alopecia Life discusses compassion, treatment expectations, and the psychosocial burden of alopecia areata.

Three FDA-approved biologics now intercept the inflammatory cascade at different points, yet Dr. Laura Bush argues a calm exam can understate real disease burden. The panel discusses when history should outweigh appearance.

Hidradenitis suppurativa often goes undiagnosed for years while patients quietly absorb pain, odor, and isolation. The panel examines why recognizing these signals early changes everything that follows.

Chantel Hillstead, a board-certified dermatology nurse practitioner, discussed how patients with hidradenitis suppurativa can prepare for unpredictable flares.

Joshua Zeichner, MD, presents phase 3 results showing topical clascoterone 5% stays well tolerated for 12 months and boosts hair density, signaling a new DHT-blocking option.

Vishal A. Patel, MD, FAAD, FACMS, discusses tan maxing, cumulative UV damage, and how clinicians can approach conversations about tanning habits.

Dermatology Times and Physicians' Education Resource will host DermNexus Congress, a two-day CME program for nurse practitioners and physician assistants, November 20–21 in Scottsdale, Arizona.

James Caleb Runyon, MSN, NP-C, shared lessons on building an advocacy initiative, developing partnerships, and balancing advocacy with clinical practice.

Amit Om, MD, discussed Mohs surgery, its high cure rates, patient education, and the importance of collaboration across dermatology care teams.

At the Dermatology Times NP/PA Connect Cutaneous Oncology Workshop in Tampa, Florida, Angad Chadha, MD, discussed his upcoming presentations on gene expression profiling and cutaneous side effects of immunotherapy.

Attendees put technique into practice during an interactive suturing session led by Tristan Hasbargen, PA-C, using individual kits and real-world clinical examples.

As chair of the new Dermatology Times NP/PA Connect Cutaneous Oncology Workshop, Tristan Hasbargen, PA-C, discusses the program's curriculum and goals live in Tampa, Florida.

New hair-loss therapies aim to block DHT at follicles, using targeted scalp delivery to reduce systemic side effects and improve male pattern baldness outcomes.

In the concluding episode, Dr. Tina Bhutani-Jacques emphasizes the importance of looking beyond clinical measures such as body surface area when evaluating treatment success in patients with plaque psoriasis.

Closing out the series, each panelist names the combination of therapies they return to most often and delivers a final word on treating HS without hesitation.

Victoria Werth, MD, reviews brepocitinib's boxed warning and expanded treatment options for dermatomyositis.

An oral JAK inhibitor, a BTK inhibitor, and GLP-1 receptor agonists are reshaping what's possible in HS. The panel previews mechanisms it expects to reach patients next.

James Caleb Runyon, MSN, APRN, FNP-C, discussed how his Closer Look Project trains personal care professionals to recognize signs of skin cancer.

Victoria Werth, MD, discusses the FDA approval of brepocitinib for dermatomyositis and its supporting VALOR trial data.

Steven Daveluy, MD, discussed mental health screening, patient conversations, and referrals for patients with chronic skin disease.

Amanda Caldwell, MSN, APRN-C, discussed assessing psoriasis beyond body surface area and incorporating patient preferences into treatment decisions.

Joshua Arbesman, MD, explains how tailored sun-safety advice balances melanoma risk, aging goals, and quality of life in all types of patients.

In the concluding segment, Dr. Tina Bhutani-Jacques discusses the rationale for initiating tapinarof 1% cream in a patient with localized plaque psoriasis who is unwilling to use topical corticosteroids because of concerns about long-term adverse effects.

In the discussion, Dr. Tina Bhutani-Jacques reviews the management of a 34-year-old man with localized plaque psoriasis who is seeking effective long-term disease control while avoiding topical corticosteroids.